drugset

drugset / Trial / NCT06888115

A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

NCT06888115 ↗

Phase 1 Completed 24 enrolled Cascade Pharmaceuticals, Inc

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Phase I Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

Timeline

Start: 2025-03-13
Primary completion: 2025-05-29
Completion: 2025-06-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CS0159	Unknown	4 mg	Oral

Indications